Shares

3 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2021

Aug 12, 2021

SELL
$3.94 - $4.92 $439,408 - $548,703
-111,525 Closed
0 $0
Q1 2021

May 17, 2021

BUY
$4.23 - $6.55 $99,591 - $154,213
23,544 Added 26.76%
111,525 $506,000
Q4 2020

Feb 19, 2021

BUY
$5.73 - $9.03 $504,131 - $794,468
87,981 New
87,981 $505,000

Others Institutions Holding CBAY

About CymaBay Therapeutics, Inc.


  • Ticker CBAY
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 84,677,904
  • Description
  • CymaBay Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing and providing therapies to treat liver and other chronic diseases. Its lead product candidate is seladelpar (MBX-8025), a selective agonist of peroxisome proliferator activated receptor delta that is in phase III clinical study for the treatments of pri...
More about CBAY
Track This Portfolio

Track Aton Ra Partners Portfolio

Follow Aton Ra Partners and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Aton Ra Partners, based on Form 13F filings with the SEC.

News

Stay updated on Aton Ra Partners with notifications on news.